Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14312991 | 0.72 | PARP1 (0.56) | PARP1SLC22A12ELANEMET | |
| SCHEMBL28849705 | 0.71 | RPS6KA5 (0.40) | PARP1SLC22A12ELANEMET | |
| SCHEMBL2066749 | 0.69 | PIK3CB (0.34) | — | |
| SCHEMBL5442677 | 0.69 | PARP1 (0.40) | PARP1 | |
| SCHEMBL6526827 | 0.63 | KMT2A (0.35) | PARP1 | |
| SCHEMBL3224526 | 0.61 | PARP1 (0.36) | PARP1 | |
| SCHEMBL3226888 | 0.61 | PARP1 (0.36) | PARP1 | |
| SCHEMBL6421055 | 0.61 | DAO (0.34) | — | |
| SCHEMBL11882632 | 0.61 | KMT2A (0.57) | — | |
| SCHEMBL828619 | 0.61 | KMT2A (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461159-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | Jannsen Pharmaceutica BV (BE) | 2013-06-11 | — | — | US | claimed |
| WO-2010068453-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | claimed |
| US-8877769-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | JANSEEN PHARMACEUTICA NV (BG) | 2014-11-04 | — | — | US | disclosed |
| US-20130245022-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | disclosed |
| US-8461159-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | Jannsen Pharmaceutica BV (BE) | 2013-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245022-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | PARP1 1766/4885SLC22A12 3852/4885ELANE 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.